Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity

Author： van den Bent M.J.   van Putten W.L.J.   Hilkens P.H.E.   de Wit R.   van der Burg M.E.L.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.38, Iss.3, 2002-01, pp. : 387-391

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neurological Monitoring of Neurotoxicity Induced by Paclitaxel/Cisplatin Chemotherapy

By Berger T.   Malayeri R.   Doppelbauer A.   Krajnik G.   Huber H.   Auff E.   Pirker R.  

European Journal of Cancer, Vol. 33, Iss. 9, 1997-08 ,pp. : 1393-1399

Elsevier

Access to resources Recommend Favorite

Neurotoxicity is not Enhanced by Increased Dose Intensities of Cisplatin Administration

By Hilkens P.H.E.   van der Burg M.E.L.   Moll J.W.B.   Planting A.S.T.   van Putten W.L.J.   Vecht C.J.   van den Bent M.J.  

European Journal of Cancer, Vol. 31, Iss. 5, 1995-01 ,pp. : 678-681

Elsevier

Access to resources Recommend Favorite

Dose-dense cisplatin/paclitaxel - a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer

By de Jongh F.E.   de Wit R.   Verweij J.   Sparreboom A.   van den Bent M.J.   Stoter G.   van der Burg M.E.L.  

European Journal of Cancer, Vol. 38, Iss. 15, 2002-10 ,pp. : 2005-2013

Elsevier

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite

A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer

By Moriwaki Toshikazu   Hirai Shinji   Hironaka Shuichi   Amagai Kenji   Soeda Atsuko   Sato Mikio   Nihei Takeshi   Hirose Mitsuaki   Matsuda Kenji   Ohkawara Atsushi   Yamaguchi Taketo   Ozeki Mitsuharu   Mamiya Takashi   Murashita Tetsuya   Hyodo Ichinosuke  

Gastric Cancer, Vol. 17, Iss. 2, 2014-04 ,pp. : 354-361

Springer Publishing Company

Access to resources Recommend Favorite